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ABSTRACT
INTRODUCTION:  Fine-needle aspiration (FNA) is a corner-
stone in diagnosing thyroid nodules. For decades, Danish 
FNA have been categorised into the groups: “FNA not per-
formed”, “Inadequate”, “Cystic”, “Inconclusive”, “Benign”, 
“Suspicious”, “Malignant” and “Information missing”. Inter-
nationally, The Bethesda Classification System (TBCS) is  
increasingly accepted, especially owing to a detailed spe-
cification of FNA suspicious for malignancy. The Danish 
“Suspicious” group is very broad and includes atypia, follicu-
lar neoplasia and FNA suspicious of other malignancies. The 
purpose of this study was to apply TBCS to the Danish 
“Suspicious” FNA group and to estimate the frequency 
of malignancy in the individual Bethesda groups (BG).
METHODS: This descriptive study is based on a prospective 
cohort from the THYKIR database. It includes 479 patients 
with a “Suspicious” FNA and surgical treatment in The Re-
gion of Southern Denmark from 2001 to 2013. Based on  
pathology records, FNA was classified according to the 
TBCS. Malignancy was determined by the histological diag-
nosis from the THYKIR database.
RESULTS: The Danish “Suspicious” group was allocated to 
the BG I, II, III, IV, V and VI with a malignancy risk of 36.4%, 
13.3%, 17.2%, 16.1%, 55.3% and 88.2%, respectively.
CONCLUSIONS: The Danish “Suspicious” group contains a 
broad spectrum of BG with varying malignancy risk. The re-
sults indicate a need for standardisation of the Danish FNA 
classification. A national introduction of the TBCS might se-
cure an international and comparable standard.
FUNDING: none. 
TRIAL REGISTRATION: not relevant. 
Thyroid carcinoma is the most frequent endocrine ma-
lignancy in Europe [1]. In 2015, The Danish Thyroid Can-
cer Database (DATHYRCA) registered 312 patients with 
thyroid cancer [2] in the Danish population of 5.6 million 
people [3]. A Danish study showed that 67% of Danish 
thyroid carcinomas are of the papillary type, 18% of the 
follicular type, 7% of the medullary type and 8% of the 
undifferentiated (anaplastic) type [4].
Palpable thyroid nodules are frequent with a preva-
lence of 5% in women and 1% in men, but only 7-15% of 
thyroid nodules are malignant [5]. Therefore, it is impor-
tant to have an accurate preoperative diagnostic tool 
cap able of discriminating between benign and malign 
thyroid nodules to reduce any unnecessary surgery. 
Fine-needle aspiration (FNA) is a cornerstone in the  
diagnostic strategy for thyroid nodules and is recom-
mended by The American Thyroid Association (ATA) 
guidelines because it is the most precise and cost-effect-
ive method for evaluation of thyroid nodules [5].
In a Danish study, the sensitivity and specificity for 
malignancy were 73.9% and 99.2%, respectively [6]. The 
positive predictive value was 89.5% and the negative 
predictive value was 97.7% [6].
Previously, there was no agreement on the number, 
types or terminology of FNA categories, which made it 
difficult to compare results between centres and na-
tions. In addition, differences between pathologists and 
clinicians in their understanding of pathology reports 
have been shown [7]. This may partly be due to vague 
descriptions such as “indeterminate” or “cannot ex-
clude”, which can lead to confusion. To resolve these 
problems, an increasing number of centres have imple-
mented The Bethesda Classification System (TBCS), 
which is the offspring of the 2007 National Cancer 
Institute Thyroid Fine Needle Aspiration State of the 
Science Conference. The aim of TBCS is to provide con-
sensus recommendations for diagnostic terminology and 
morphological criteria to increase the quality and repro-
ducibility of thyroid cytology reporting [8]. TBCS is rec-
ommended by the 2015 ATA guidelines [5].
TBCS consists of six diagnostic categories: I Non-
diagnostic/Unsatisfactory; II Benign; III Atypia of unde-
termined significance/Follicular lesion of undetermined 
significance (AUS/FLUS); IV Follicular neoplasm/Sus pi-
cious for follicular neoplasm (FN/SFN); V Suspicious for 
malignancy (SFM) and VI Malignant [8].
In Denmark, thyroid cytology is categorised into 
eight groups as defined in The Danish Thyroid Surgery 
Database (THYKIR): “FNA not performed”, “Inad-
equate”, “Cystic”, “Inconclusive”, “Benign”, “Suspi-
cious”, “Malignant” or “Information missing”. The 
Danish “Suspicious” group is very broad and includes 
follicular neoplasia, atypia and FNA suspicious for other 
malignancy. A recent Danish study found the frequency 
of malignancy in the Danish “Suspicious” FNA group to 
be 22.4% [9]. 
A competent classification system for FNA is im-
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port ant because of its role in treatment decision. Due to 
the broad nature of the Danish “Suspicious” group, it is 
of great interest to investigate the distribution of FNA 
results and the malignancy risk in each Bethesda group 
(BG) when TBCS is applied to the Danish “Suspicious” 
group. A classification of the Danish “Suspicious” group 
based on TBCS has never been done. The purpose of this 
study was to apply TBCS to the Danish “Suspicious” FNA 
group and to estimate the frequency of malignancy in 
each individual BG.
METHODS
This is a descriptive study based on a prospectively regis-
tered cohort from the THYKIR database, which contains 
data on thyroid surgery performed in Denmark. Among 
the 3,449 patients who had thyroid surgery performed 
at the departments of Otorhinolaryngology, Head & 
Neck Surgery in the Region of Southern Denmark 
(Odense University Hospital, Vejle Hospital, Esbjerg Hos-
pital and Soenderborg Hospital) from 1 January 2001 to 
31 December 2013, 491 patients had a “Suspicious” FNA 
and were included in this study. The patients were 
linked by their personal identity number to the National 
Pathology Register (PATOBANKEN) to identify their path-
ological records.
Of the 491 patients, 12 patients were excluded; 
four due to lack of cytological descriptions of FNA and 
eight due to insufficient data concerning their histo-
logical diagnosis. The final study population consisted of 
479 patients (Figure 1).
Cytological descriptions of FNA from PATOBANKEN 
were retrospectively analysed and classified according 
to TBCS without knowledge of the histological diagnosis. 
In case of uncertainty about categorisation, a team con-
sisting of two clinicians and one pathologist made a final 
consensus-based decision. This was the case in 48 of 479 
(10%) cases. If the team could not reach an agreement, 
the pathologist made the final decision.
When the patient had more than one FNA, the one 
with the highest (“most malignant”) BG was chosen. 
Pathologists at university hospitals see more FNAs than 
pathologists at smaller hospitals and it was considered 
reasonable to assume that pathologists at university 
hospitals had more expertise. Therefore, if the FNA had 
been revised by a university hospital, their diagnosis was 
chosen regardless if it was a higher or lower BG than the 
original diagnosis.
The frequency of malignancy was subsequently de-
termined in each BG by the histological diagnosis ex-
tracted from the THYKIR database. Data were stored, 
processed and analysed anonymously in an Excel file 
within SharePoint. The study was approved by the 
Danish Data Protection Agency/Region of Southern 
Denmark (record no.:15/36370 and 15/28871). The in-
formation was identified from already approved data-
bases, and no patient records were used.
Trial registration: not relevant.
RESULTS
The study population included 479 patients; 371 (77.5%) 
women and 108 (22.5%) men. The age ranged from 16 
to 91 years with a median age of 53 years at the time of 
surgery. The FNAs were classified into six groups accord-
ing to TBCS, and the frequency of malignancy in each BG 
was determined based on the histological diagnosis. The 
results are presented in Table 1. A total of 43 (9.0%) of 
the patients had an FNA classified into BG I, II or VI. The 
most dominant group was BG IV followed by BG III, and 
combined these groups contained 398 (83.1%) patients.
DISCUSSION 
This is the first study addressing the distribution of Dan-
ish FNA according to TBCS and determining the frequen-
cy of malignancy in each BG for the Danish “Suspicious” 
group. TBCS, first published by Cibas et al in 2009, con-
tained estimates of the cancer risk in each BG based on 
a literature review and expert opinion [8]. Many centres 
have published their frequency of malignancy after 
adopting TBCS and, despite variability, their results for 
BG IV-VI were overall comparable with the range esti-
mated by Cibas et al [8, 10, 11]. 
FIGURE 1
Flow chart of the study population.
Patients not included:
• Patients without a “Suspi-
cious” FNA (n = 2,958)
Patients included:
• Patients with a “Suspicious” 
FNA (n = 491)
Patients excluded:
• Detailed cytology descrip-
tion missing (n = 4)
• Insufficient data regarding 
histological diagnosis  
(n = 8)
Patients registered in the 
THYKIR database in the Region 
of Southern Denmark, from 1 
January 2001 to 31 December 
2013 
(N = 3,449)
The study population
(n = 479)
FNA = fine-needle aspiration; THYKIR = The Danish Thyroid Surgery 
 Database.
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The precise risk of malignancy in group I-III is diffi-
cult to assess from the literature. The studies often only 
included patients with surgical follow-up, and excluded 
those without. The patients who underwent surgery 
would presumably have other signs of malignancy lead-
ing to surgery making the risk of overestimating the ma-
lignancy risk in BG I-III substantial.
Our study found a higher frequency of malignancy 
in BG I (36.4%) and II (13.3%), and a lower frequency in 
BG VI (88.2%) compared with Cibas et al, where the risk 
of malignancy was estimated to 1-4%, 0-3% and 97-99%, 
respectively [8]. This was most likely due to the fact that 
our study did not include patients with a FNA classified 
as “Inadequate”, “Cystic”, “Inconclusive”, “Benign” or 
“Malignant”. Our study may therefore have overesti-
mated the frequency of malignancy in BG I and II, and 
underestimated malignancy in BG VI. Hence, only our re-
sults from BG III, IV and V can truly be compared with 
the literature.
In our study, the frequency of malignancy for BG III 
was 17.2%, which was higher than the 5-15% estimated 
by Cibas et al [8]. Among other studies, the results for 
the BG III have shown variability, and many have implied 
that the malignancy risk is greater than estimated buy 
Cibas et al [8, 10-12]. Ho et al found the frequency of 
malignancy to be 26.6-37.8% [12]; a review by Ohori et 
al found a mean malignancy of 26.3% [11], while a meta-
analysis of Bongiovanni et al only showed a slightly  
higher risk of 15.9% [10] than Cibas et al [8]. As men-
tioned, not all patients in BG III had surgical follow-up, 
and the variation in the literature might be due to the 
use of different criteria for selecting patients for opera-
tion. If it is assumed that all Danish patients with AUS/
FLUS (BG III) are categorised as “Suspicious”, almost all 
are surgically treated, and the risk of an overestimation 
is limited. However, as our study did not evaluate all 
Danish FNA, it is possible that Danish groups such as the 
“Inconclusive” group may contain some AUS/FLUS, mak-
ing our BG III a selective group with a risk of overesti-
mating the malignancy risk. This might also explain why 
our frequency of malignancy, surprisingly, was higher in 
BG III than in BG IV as it is assumed that all FN/SFN  
(BG IV) are categorised as “Suspicious” and operated. 
Therefore, the malignancy risk is most likely not overes-
timated in our BG IV. 
Another problem is the tendency to overuse BG III. 
It is recommended that BG III is used only as a last resort 
and to limit the use to ≤ 7% of all FNA [8]. In our study, 
18.2% were classified as BG III, but this cannot be com-
pared with the limit of 7% as this is only the distribution 
in the “Suspicious” group.
Most of the patients (64.9%) with a “Suspicious” 
FNA were classified into BG IV, and 16.1% of these had a 
malignant histology. This is in the lower end of the 15-
30% that Cibas et al suggested [8] and much lower than 
reported by Bongiovanni et al (26.1%) [10] and Ohori et 
al (26.4%) [11].
The frequency of malignancy in BG V (55.3%) was 
lower than both the 60-75% estimated by Cibas et al [8], 
and the frequencies found by Bongiovanni et al (75.2%) 
[10] and Ohori et al (79.1%) [11].
The differences between our results for BG III-V and 
the literature might be explained by a different distribu-
tion in Denmark, but might also be due to misclassifica-
tion because the cytological descriptions were not made 
with subsequent reclassification into TBCS in mind. Fur-
thermore, an FNA classified as “Suspicious” resulted in 
the same treatment regardless if it was described as 
AUS, FN, SFN or SFM. Pathologists might have been 
more precise in distinguishing borderline cases if the 
treatment of these had been different. Due to the rela-
tively low dietary iodine intake in Denmark, the national 
diagnostic strategy for thyroid nodules include thyroid 
scintigraphy. This is not the case in the US or in most 
European countries. Therefore, direct comparisons of 
BG results have to be interpreted with caution.
Combined, the malignancy risk in the Danish “Sus-
picious” FNA group was 22.4% [9]. Our study showed 
that if “Suspicious” FNA are classified into TBCS, the ma-
lignancy risk was much higher in BG V than in BG III and 
IV. This indicates that patients would get a more accur-
ate risk estimation by using TBCS which is important to 
both the patients and the doctors involved. However, 
we do not expect significant changes in the choice of 
surgical procedure, i.e. hemi-throidectomy versus total 
thyroidectomy. However, a more precise knowledge 
about the risk of malignancy may influence the surgical 
setup concerning the availability of frozen section his-
tology and the experience of the surgical team. Fur-
thermore, a more precise communication between the 
pathologist and clinicians will benefit the patient. 
TABLE 1
Distribution of fine-needle aspirations in the Danish “Suspicious” group when classified according to  
The Bethesda Classification System, and the frequency of malignancy in each Bethesda Group.
Bethesda Group n (%a) Malignant cases, n (%b)
I: Non-diagnostic/unsatisfactory   11 (2.3)     4 (36.4)
II: Benign   15 (3.1)     2 (13.3)
III: Atypia of undetermined significance/follicular 
lesion of undetermined significance 
  87 (18.2)   15 (17.2)
IV: Follicular neoplasm/suspicious for follicular 
neoplasm
311 (64.9)   50 (16.1)
V: Suspicious for malignancy   38 (7.9)   21 (55.3)
VI: Malignant   17 (3.5)   15 (88.2)
Total 479 (100) 107 (22.3)
a) % of the 479 patients
b) % of malignant cases in each Bethesda Group
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Cytological descriptions may be unclear, making the clin-
ician insecure and perhaps more prone to resort to sur-
gery than surveillance. By forcing the pathologist to give 
a precise Bethesda classification this may be prevented.
Patients with FNA classified as “Suspicious” were 
anticipated to be distributed among BG III, IV and V, but 
9% were classified in BG I, II or VI. This implies that the 
Danish “Suspicious” group cannot be compared uncrit-
ically with BG III-V from other centres. This may be due 
to different diagnostic and morphological criteria in the 
two classification systems and indicates the importance 
of having the same classification systems across centres 
and nations to be able to compare data. However, the 
most important reason for the 9% classified as BG I, II 
and VI is presumably miscommunication between the 
pathologist and the clinicians, as it were the clinicians 
who initially interpreted the cytological description and 
allocated the FNA to the “Suspicious” group in the 
THYKIR database. In some cases, the cytological descrip-
tion was diffuse and without a clear conclusion, making 
an unambiguous registration very difficult. Therefore, 
the initial interpretation performed by the registering 
clinician and the interpretation performed by our team 
may differ significantly. This very strongly implies the 
need for a standardised reporting system, such as TBCS, 
to improve communication among pathologists and  
clinicians.
An important limitation to this study was that the 
FNA were classified into TBCS categories based on inter-
pretation of cytological descriptions and not directly by 
the pathologist performing the cytological examination. 
Another limitation was that data were accepted as re-
ported to the THYKIR database. This is an issue because 
errors in the reporting process may occur, which might 
also be part of the explanation for some of the 9% clas-
sified as BG I, II or VI. Furthermore, accepting the histo-
logical diagnosis as the correct diagnosis to the FNA 
could be problematic because the study design did not 
guarantee that the nodule biopsied was the same as the 
one containing a malignant diagnosis.
Among the strengths in this study were the pro-
spective data collection from both THYKIR and PATO-
BANKEN, the coverage of a specific geographical referral 
area (The Region of Southern Denmark) and that classifi-
cation of the FNA into TBCS occurred without knowledge 
of the histological diagnosis. Furthermore, the usage of 
the THYKIR database with a completeness of around 
97% [13] and the ability to find all the patients’ path-
ology records via their personal identity number further 
strengthen the study. The mentioned strengths reduce 
the risk of bias and increase the generalisability of the 
study.
This study indicates the frequency of malignancy in 
each BG for the Danish “Suspicious” group. To deter-
mine the exact distribution of malignancy, further  
studies are needed to investigate, e.g., the frequency of 
malignancy after implementing TBCS or to reexamine 
the FNA instead of using pathological records.
CONCLUSIONS
The Danish “Suspicious” FNA group contains a broad 
spectrum of BG with varying malignancy risk. The malig-
nancy risk for the BG I, II, III, IV, V and VI was 36.4%, 
13.3%, 17.2%, 16.1%, 55.3% and 88.2%, respectively. 
The results indicate a need for standardisation of the 
Danish FNA classification. A national introduction of 
TBCS might secure an international and comparable 
standard.
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